The Oncology Deep Dive

For the first time in 10 years, patients with pretreated head and neck cancer have a new FDA-approved option. And Boehringer Ingelheim just committed up to $7B to six early-stage cancer drugs from China.In this week's Oncology Deep Dive, we unpack the Monday Morning Oncology Brief (Nov 3–9, 2026) for clinicians, investors and industry:🔹 Head and neck cancer: J&J's Rybrevant Faspro wins accelerated approval. The EGFR × MET bispecific shrank tumors in 42% of patients whose cancer had progressed after chemo and immunotherapy. One expert calls it practice-changing; another stresses it doesn't apply to HPV-related cancers, a fast-growing group. Who actually benefits?🔹 ASH 2026 preview: T-cell engagers move toward frontline myeloma. Early data for J&J's trispecific ramantamig show every evaluable patient responding in a small first cohort, and Pfizer's Elrexfio shows strong results with higher infection rates. Can community clinics safely give these drugs, or do they still belong in academic centres?🔹 Boehringer × Sino Biopharm: $358M upfront, up to $7B in total, for six preclinical ADC and T-cell engager programs. Why is big pharma paying this much, this early, for drugs not yet tested in people, and why is China now the place to shop?⚡ Lightning round: Q3 beats from Pfizer, Amgen, BioNTech and Moderna (Amgen's Imdelltra keeps surging); BioNTech's gotistobart nearly doubles survival in squamous lung cancer; SITC 2026 in Phoenix; and Ibrance slows ahead of Medicare price negotiation in January 2027.The question we leave you with: if the strongest drugs move to day one, how does the next small biotech ever prove it's better?For clinicians, investors and anyone who wants clear, jargon-free oncology news every Monday. Follow the show so you don't miss next week's briefing.#Oncology #HeadAndNeckCancer #ASH2026 #MultipleMyeloma #Biotech #China #ADC #Bispecifics #JNJ #PharmaDisclaimer: AI-generated from publicly available news. Not medical or investment advice. May contain errors — verify against primary sources.Chapters:00:00 Big pharma shops abroad and moves its best drugs earlier00:39 This week's Monday Morning Oncology Brief00:55 Head and neck cancer: a 10-year wait ends01:56 OrigAMI-4: tumors shrink in 42% of patients02:40 How an EGFR × MET bispecific works03:23 J&J takes Rybrevant beyond lung cancer03:44 Keytruda first, Rybrevant second04:19 Debate: practice-changing or limited by HPV status?05:49 Why HPV-unrelated cancers respond differently06:33 ASH 2026 preview: myeloma moves fast07:13 Ramantamig's early frontline data07:51 How a trispecific antibody works08:31 Off-the-shelf drugs vs. CAR-T09:33 Other ASH signals: Servier and Calquence09:56 Debate: can community clinics give these drugs?11:52 Boehringer × Sino Biopharm: the $7B China bet12:30 Deal terms: $358M upfront13:06 ADCs and three strategic patterns14:10 Debate: why pay so much, so early?15:37 Lightning round15:45 Q3 earnings: Imdelltra and BioNTech16:30 SITC 2026 in Phoenix16:57 Ibrance and Medicare price negotiation17:26 The takeaway: hitting cancer harder on day one18:30 Can small biotechs still compete?19:13 Sign-off

Every major oncology company beat expectations this quarter, and most raised their 2026 guidance. So what drove it? Two things at once: protecting blockbusters like Keytruda and Opdivo ahead of the 2028 biosimilar cliff, and a group of newer drug platforms now big enough to carry earnings on their own.In this week's Oncology Deep Dive, we unpack the Monday Morning Oncology Brief and what it means for patients, portfolios and clinical practice:🔹 Defending the blockbusters. Companies are moving patients from IV infusions to under-the-skin injections before cheaper biosimilars arrive. Merck's subcutaneous Keytruda reached $830M in its first full quarter, while BMS's subcutaneous Opdivo sits at about 14% conversion. Is this a real benefit for patients, or mainly a way to extend patent protection?🔹 The new growth engines. ADCs, bispecifics and other next-generation therapies are driving growth, with Enhertu up 35% and Jaypirca up 59%. Are they meaningfully extending survival, or adding expensive incremental gains?🔹 What to watch: FY2027 guidance at the January investor days, not new trial data, is the next real signal.⚡ Lightning round: Genmab's petosemtamab beats Keytruda in head and neck cancer; AbbVie's Epkinly in frontline lymphoma (company-reported, awaiting peer review); Pfizer's Elrexfio wins in myeloma, with higher infection rates; Geron's imetelstat fails in myelofibrosis; Astellas bets $1.34B on reviving IL-12; and an immunotherapy dose-stretching trial stopped early.The question we leave you with: if patients need to stay on frequent immunotherapy, and more of them move to premium-priced maintenance injections, how will health systems pay for millions of patients living for years on branded treatment?For clinicians, investors and anyone who wants clear, jargon-free oncology news every Monday. Follow the show so you don't miss next week's briefing.#Oncology #Q3Earnings #Keytruda #Opdivo #Biosimilars #ADC #Bispecifics #CancerResearch #Biotech #PharmaDisclaimer: AI-generated from publicly available news. Not medical or investment advice. May contain errors — verify against primary sources.Chapters:00:00 What really drove oncology's best quarter00:23 Welcome to The Oncology Deep Dive00:36 Every major reporter beats: franchise rotation01:03 The defence: from IV drip to under-the-skin shot01:42 The 2028 biosimilar cliff02:32 Debate: patient benefit or patent repackaging?03:20 Merck's subcutaneous Keytruda vs. BMS's Opdivo04:14 The offence: next-generation drug platforms04:39 ADCs and bispecifics in plain language05:06 Enhertu and Jaypirca drive growth05:30 Debate: real survival gains or expensive increments?06:06 What to watch: FY2027 guidance in January06:31 Lightning round06:35 Petosemtamab beats Keytruda in head and neck cancer06:57 Epkinly in lymphoma: awaiting peer review07:30 Elrexfio in myeloma: efficacy vs. infection risk07:50 Geron's imetelstat fails in myelofibrosis08:04 Astellas bets $1.34B on reviving IL-1208:32 Immunotherapy dose-stretching trial stopped early08:58 The takeaway: franchise rotation09:18 Who pays for decades of premium injections?09:46 Sign-off

Moderna and Merck's individualized mRNA cancer vaccine just won its first Phase 3 — and the stock fell sharply the same day. How can a scientific breakthrough be a commercial disappointment?In this special ESMO 2026 edition of The Oncology Deep Dive, we cut through the noise from Madrid: 10 headline calls, what happened, why it matters for patients and portfolios, and the debates echoing through the halls.🔹 mRNA vaccine wins in melanoma. INTerpath-001 (intismeran + Keytruda) cut the risk of recurrence or death by 42% after surgery. Practice-changing, or a melanoma-only success with a 6–9 week manufacturing wait?🔹 Kisqali's benefit keeps growing. Six-year NATALEE data in early HR+/HER2- breast cancer show a survival gain that widens years after patients stop the drug.🔹 Small cell lung cancer breaks through. Tarlatamab + durvalumab (DeLLphi-305) helps patients live about eight and a half months longer, but can community oncologists manage the immune side effects?🔹 A head-to-head KRAS cage match. Roche's divarasib beats the first-generation G12C drugs in Krascendo 1, with survival and liver-safety advantages.🔹 Blocking the tumor's detour. Osimertinib + savolitinib (SAFFRON) beats chemo in MET-driven resistant lung cancer. Targeted roadblocks or ADC smart bombs?🔹 Merck's TROP2 ADC wins twice. Sac-TMT + Keytruda in PD-L1-low lung cancer, and sac-TMT alone in advanced endometrial cancer after IO, where survival had stagnated for decades.🔹 Gastric cancer's survival paradox. AstraZeneca's Claudin 18.2 ADC doubles survival even though progression-free survival missed. How?🔹 Ivonescimab beats durvalumab head-to-head in biliary tract cancer (HARMONi-GI1). But can a China-only trial change US practice?🔹 Chemo-free surgery bookends in bladder cancer. Durvalumab + enfortumab vedotin (VOLGA) for patients too frail for cisplatin.The takeaway: oncology is moving its most powerful weapons into the earliest stages of disease, trying to cure cancer on the first attempt rather than salvage it at the end.For clinicians, investors and anyone who wants clear, jargon-free oncology news every Monday. Follow the show so you don't miss next week's briefing.#ESMO2026 #Oncology #CancerResearch #mRNA #Moderna #Merck #ADC #LungCancer #BreastCancer #BiotechDisclaimer: AI-generated from publicly available news. Not medical or investment advice. May contain errors — verify against primary sources.Chapters:00:00 Moderna's vaccine wins, Wall Street sells00:25 Welcome to our ESMO 2026 special00:43 INTerpath-001: mRNA vaccine wins in melanoma01:04 The individualized "wanted poster"01:54 Why the stock fell02:49 Debate: practice-changing or melanoma-only?03:24 NATALEE: Kisqali's six-year survival data04:07 A benefit that grows after stopping the drug04:51 DeLLphi-305: tarlatamab in small cell lung cancer05:52 The catch: cytokine release syndrome06:29 Krascendo 1: divarasib vs. first-gen KRAS drugs07:19 Liver safety and the expert split07:58 SAFFRON: osimertinib + savolitinib08:50 Targeted roadblocks vs. ADC smart bombs09:15 Sac-TMT + Keytruda in PD-L1-low lung cancer10:02 Merck's Keytruda moat10:19 TroFuse-005: sac-TMT in endometrial cancer11:27 Claudin 18.2 ADC in gastric cancer12:18 Survival without PFS: the paradox12:55 HARMONi-GI1: ivonescimab beats durvalumab13:42 Can a China-only trial change US practice?14:03 VOLGA: chemo-free bookends in bladder cancer15:08 The takeaway: curing cancer on the first try15:47 Sign-off

Keytruda, the most successful cancer drug ever, gets its first official biosimilar challenger in the same week that an mRNA cancer vaccine built to pair with it misses its primary endpoint. Is the future of oncology arriving, just not the way anyone drew it up?In this Monday Morning Oncology Brief (Oct 13–19, 2026), we unpack the three stories that moved the needle:🔹 BioNTech’s BNT113 misses on progression. The Phase 2/3 AHEAD-MERIT trial failed its PFS endpoint in HPV16+ head and neck cancer, and BioNTech disclosed no numbers. Overall survival is still being tested, so the trial isn’t over. If an mRNA vaccine struggles against an obvious viral target, what does that mean for the field? And how does it compare with Merck and Moderna’s INTerpath-001, which presents at ESMO on Oct 25?🔹 No chemo, no transplant in Ph+ ALL. NEJM data show ponatinib plus blinatumomab beating imatinib plus chemotherapy as frontline therapy. Nearly nine in ten patients were alive without a disease event at two years, versus about two-thirds on chemo. One expert calls it practice-changing, but is two years of follow-up enough to skip a transplant?🔹 The first Keytruda biosimilar BLA. The FDA accepted Formycon/Zydus’s FYB206, with a decision expected around Q3 2027. That makes the biosimilar calendar real for a ~$30B franchise, compresses pricing for every Keytruda combination, and raises the stakes for Merck’s subcutaneous defence.⚡ Lightning round:Anktiva’s early label expansion in papillary bladder cancer.Gilead and Vir’s $135M upfront deal for masked T-cell engagers.Europe follows the US on Revolution Medicines’ daraxonrasib in pancreatic cancer.Talvey moves into 2L myeloma in the EU.SystImmune’s silent Phase 3 registration for its HER2 ADC in bladder cancer.From blunt force to precision, oncology is optimizing everything at once. What happens to trial design when the standard of care is this refined?No episode last week; we were on vacation. Next week: our post-ESMO 2026 episode from Madrid.#Oncology #mRNA #Leukemia #Biosimilars #Keytruda #BioNTech #ESMO2026 #Pharma #BiotechDisclaimer: AI-generated from publicly available news. Not medical or investment advice. May contain errors — verify against primary sources.Chapters:00:00 Keytruda's first clone vs. BioNTech's mRNA stumble00:33 Welcome to The Oncology Deep Dive00:55 BioNTech's BNT113 misses its primary endpoint01:13 How an mRNA cancer vaccine works: the "wanted poster"01:53 No numbers disclosed: what BioNTech isn't saying02:26 Why HPV16 was BioNTech's most tractable bet03:02 The debate: is waiting for overall survival a pivot?04:19 What to watch: Merck & Moderna's INTerpath-001 at ESMO04:53 Ph+ leukemia: chemo-free ponatinib + blinatumomab05:28 Precision strike + matchmaker: how the combo works05:49 Nine in ten vs. two-thirds: the survival gap06:21 Practice-changing: no transplant needed?06:38 The debate: is two years of follow-up enough?07:11 Keytruda's first biosimilar application07:36 What a biosimilar is: cloning a vintage wine08:05 2027: the biosimilar calendar becomes real08:19 Pricing pressure and Merck's subcutaneous defence08:46 Lightning round08:53 Anktiva expands in bladder cancer09:10 Gilead × Vir: masked T-cell engagers09:26 Europe follows the US on daraxonrasib09:45 Talvey moves into earlier myeloma10:00 SystImmune's silent Phase 3 for T-bren10:12 From blunt force to precision10:47 See you in Madrid

Why would AstraZeneca pay $2 billion for just 12% of Summit Therapeutics? And why is Lilly's Jaypirca skipping straight to first-line CLL? This week's theme: oncology is done saving its best drugs for later.In this Monday Morning Oncology Brief, we unpack the three biggest shifts of the week:🔹 Lilly's Jaypirca (pirtobrutinib) moves to first line in CLL. The FDA approval is backed by an 80% reduction in progression risk versus chemo-immunotherapy in BRUIN CLL-313. It puts pressure on AbbVie's Imbruvica and AstraZeneca's Calquence. But should doctors use their best rescue drug on day one?🔹 AstraZeneca's $2B Summit deal. A 12% stake de-risks Summit ahead of its November 14 FDA decision and pairs ivonescimab, a PD-1/VEGF bispecific, with AstraZeneca's Claudin 18.2 ADC in GI cancers. A follow-on deal with Daiichi Sankyo extends the strategy to triple-negative breast cancer. Is this AstraZeneca's answer to Merck's Keytruda-plus-ADC playbook?🔹 Roche's evERA data in the NEJM. Giredestrant + everolimus cut progression risk by 62% in ESR1-mutated ER+/HER2- breast cancer after CDK4/6 inhibitors. It's an all-oral, chemo-free option with no photopsia.⚡ Rapid fire:Lilly exits its Foghorn collaboration on a SMARCA2 degrader.Teva wins FDA approval for its Xgeva biosimilar.Novocure's tumor-treating fields device gets approved for pancreatic cancer in Japan.AstraZeneca and HUTCHMED file savolitinib + Tagrisso in MET-driven lung cancer.If the best drugs now go first, what happens to the pipeline of second- and third-line rescue therapies?Subscribe for a new oncology brief every Monday.#Oncology #CLL #BreastCancer #Pharma #Biotech #AstraZeneca #Lilly #RocheChapters:00:00 Oncology stops saving its best drugs for later01:09 Lilly's Jaypirca wins frontline FDA approval in CLL01:41 Superglue vs master key: covalent vs non-covalent BTK inhibitors02:28 BRUIN CLL-313: 80% lower progression risk vs chemo03:04 Pressure on AbbVie's Imbruvica and AstraZeneca's Calquence04:18 The debate: use your best rescue drug on day one?05:46 AstraZeneca's $2B stake in Summit Therapeutics06:43 Why a minority stake: de-risking Summit's November FDA decision07:37 Ivonescimab + Claudin 18.2 ADC: stacking mechanisms in GI cancers09:09 Taking on Merck's Keytruda + ADC playbook09:52 Daiichi Sankyo extends the bet to triple-negative breast cancer10:15 Roche's evERA trial: giredestrant + everolimus10:57 How oral SERDs shred the estrogen receptor11:44 62% lower progression risk in ESR1-mutated breast cancer12:37 No photopsia: Roche's edge over rival oral SERDs13:53 Rapid fire: Lilly exits Foghorn's SMARCA2 degrader14:53 Teva's Degevma, a biosimilar to Amgen's Xgeva15:23 Novocure's tumor-treating fields approved for pancreatic cancer in Japan16:02 AstraZeneca and HUTCHMED file savolitinib + Tagrisso16:40 The end of step therapy: what happens to rescue drugs?

In this episode:🔹 Kidney cancer: FDA approves Merck and Eisai's Welireg + Lenvima after immunotherapy, beating Exelixis' Cabometyx in a Phase 3 trial for the first time. But with more than 70% of patients having severe side effects, is it a real win?🔹 Multiple myeloma: AbbVie's etentamig posts a record 0.40 hazard ratio with no severe neurotoxicity. J&J fights back by pushing Tecvayli into earlier lines, and BMS's iberdomide doubles MRD negativity as its successor to Revlimid.🔹 Who decides? Why hospital logistics, payer coverage and infrastructure now shape treatment choices as much as the trial data.🔹 Rapid fire: Bayer's Nubeqa, Merck's TROP2 antibody-drug conjugate, BeOne's liver cancer bet, and the PD-1/VEGF bispecific race.Oncology is no longer just pharmacology. It's choreography. But what does "cure" mean when the playbook changes every six months?#Oncology #CancerResearch #MultipleMyeloma #KidneyCancer #Pharma #BiotechDisclaimer:AI-generated from publicly available news. Not medical or investment advice. Maycontain errors — verify against primary sources.00:00 Oncology's sequencing paradox01:11 Kidney cancer: FDA approves Merck & Eisai's Welireg + Lenvima01:35 The biology: VHL, HIF-2α and a two-front siege02:57 LITESPARK-011: dethroning Exelixis' Cabometyx03:52 The toxicity debate: 71.6% severe side effects05:33 Overall survival: why missing significance isn't the end06:36 What's at stake for Eisai, Merck & Bayer07:02 Multiple myeloma: AbbVie's etentamig at IMS 202608:07 Second-gen bispecifics: the "gentle bouncer"09:26 Record 0.40 hazard ratio & zero severe neurotoxicity10:25 J&J strikes back: moving Tecvayli into earlier lines12:34 BMS's iberdomide: hijacking the cell's garbage disposal14:26 Life after Revlimid: what's riding on it for BMS15:04 Experts divided: CAR-T vs bispecifics vs CELMoDs16:04 Hospital logistics now decide treatment17:43 Rapid fire: Nubeqa, Merck's TROP2 ADC, BeOne, PD-1/VEGF18:40 From pharmacology to choreography: redefining "cure"

Three stories dominated oncology this week — and each one redefines what it takes to win. First, Eli Lilly's FDA approval of imlunestrant locks down ESR1-mutated breast cancer with a clinical moat that AstraZeneca's failed SERENA-4 trial couldn't crack, while Roche pivots to a tolerability play in early-stage disease. Then, Curium's Bexlutry shatters Novartis's radioligand monopoly using the exact same molecule, proving that in the age of decaying isotopes, logistics can trump R&D. Finally, five CHMP recommendations out of Europe reshape the competitive map — from Enhertu's leap into curative-intent adjuvant therapy to a Keytruda–Padcev combination that slams the door on bladder cancer competitors. Plus a lightning round covering Amgen access wins, GSK's $750M myeloma deal, and a wave of stealth trial registrations signaling a defensive land grab across lung and breast cancer.Disclaimer: AI-generated from publicly available news. Not medical or investment advice. May contain errors — verify against primary sources.(00:00) Introduction & What's Ahead This Week(00:52) Lilly's Imlunestrant: FDA Approval & the ESR1 Mutation(01:38) How Tumors Outsmart Hormone Therapy(02:30) SERDs: A New Mechanism of Action(02:53) EMBER-3 Trial Results — Doubling Progression-Free Survival(03:38) AstraZeneca's SERENA-4 Failure & Lilly's Clinical Moat(04:46) Roche's Strategic Pivot to Early-Stage Breast Cancer(05:59) Curium's Bexlutry vs. Novartis's Lutathera(06:30) How Radioligand Therapies Work(07:17) The 505(b)(2) Pathway — Regulatory Shortcut or Disruption?(08:32) The Supply Chain Battle — Decaying Isotopes & Logistics(10:21) What Bexlutry Means for Radiopharmaceutical Investment(11:03) Europe's Regulatory Wave — Five CHMP Recommendations(11:49) Enhertu's Leap from Palliative to Curative Intent(13:52) PARP Inhibitor Commoditization vs. Market Lock-Out(15:29) Keytruda + Padcev Corner the Bladder Cancer Market(16:13) Lightning Round — Five Headlines in Five Minutes(17:43) Closing: The Evolving Definition of a Commercial Moat

What happens when a cancer drug works exactly as designed — stops the tumor for months — but the patient dies sooner? That paradox runs through the biggest oncology dataweekend of the year.We distill the data drop from the World Conference on Lung Cancer (WCLC) in Seoul: Ivonescimab beating Keytruda head-to-head in first-line non-small cell lung cancer, theDESTINY-Lung04 survival paradox, two same-day breakthroughs that revived smallcell lung cancer after decades of stagnation, and what the wave of genericsmeans for the oncology "blockbuster."We cut through the jargon on bispecific antibodies, antibody-drug conjugates, and BiTEs — and why sequencing may now matter as much as the drug itself.Disclaimer:AI-generated from publicly available news. Not medical or investment advice.May contain errors — verify against primary sources.00:00 The Survival Paradox00:32 Welcome to the Deep Dive01:19 HARMONI-2: Ivonescimab vs Keytruda02:25 How Bispecific Antibodies Work03:13 The Survival Numbers04:18 The Single-Region Trial Caveat05:18 Merck's Response06:04 DESTINY-Lung04: The Paradox06:40 How Antibody-Drug Conjugates Work08:10 Why the Survival Paradox Happens09:29 A Curveball: Sevabretinib11:10 RESILIENT-3: Cullinan vs J&J14:37 Small Cell: The Graveyard Awakens16:12 Amgen's BiTE: Molecular Handcuffs17:09 Sequencing, Not Competing18:08 Diagnostics & Disease Interception19:38 Where the Venture Capital Flows20:22 The Generics Reality Check21:07 The End of the Blockbuster Era?